Skip to main content Skip to main navigation menu Skip to site footer
  • \
    Start Submission Become a Reviewer

    Biomarkers of Cerebral Amyloid Angiopathy and Neuropathological Relationship with Alzheimer's Disease

    • Ting Jiang
    • Wenying Qiu
    • Jun Ni
    • Yuhui Sha
    • Xiangsha Yin
    • Xiaojing Qian


    Abstract

    Cerebral amyloid angiopathy (CAA), characterized by beta-amyloid (Aβ) deposits within small- to medium-sized blood vessels of the brain and leptomeninges, is known to be associated with an elevated risk of lobar intracerebral hemorrhage. Clinical diagnosis of CAA is complicated due to the limited diagnosis methods and lack of biomarkers for this disease. It was found that CAA has a significantly high probability of comorbidity with Alzheimer's disease (AD) due to the similar neuropathological characteristics known as amyloid-related imaging abnormalities (ARIA). Anti-Aβ monoclonal antibody therapy has been extensively investigated in the treatment of AD patients and applied in several clinical trials worldwide. However, common side effects such as hemorrhage and edema may occur for patients with preclinical or asymptomatic CAA when using antibody therapy. Therefore, it is crucial to identify CAA comorbidity in AD patients before starting anti-Aβ monoclonal antibody therapy. This review summarizes the clinical diagnostic methods and related biomarkers for AD and CAA. Further investigation of CAA for its neuropathological relationship with AD and the discovery of novel biomarkers may pave the way for a more accurate diagnosis and effective prevention of harmful side effects during treatment. It is of great importance to avoid adverse outcomes such as cerebral hemorrhage and edema caused by CAA in the treatment of AD and CAA comorbid patients.

    Keywords: Alzheimer's disease Cerebral amyloid angiopathy Lecanemab
    Section

    References

    1. 1. M Canevelli, N Vanacore, et al. Overtreating Alzheimer's Disease. J Prev Alzheimers Dis. 2021;8(2):234-236.
    2. 2. Hardy J, Selkoe DJ.The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.Science.2002 Jul 19;297(5580):353-6.
    3. 3. Clifford R Jack Jr, J Scott Andrews, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024 Aug;20(8):5143-5169.
    4. 4. Joseph Therriault, Nicholas James Ashton, et al. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology. EBioMedicine. 2024 Apr:102:105046.
    5. 5. Bales KR, O’Neill SM, Pozdnyakov N, Pan F, Caouette D, Pi Y, et al. Passive immunotherapy targeting amyloid-beta reduces cerebral amyloid angiopathy and improves vascular reactivity. Brain 2016; 139(Pt 2): 563-77.
    6. 6. Greenberg SM, Bacskai BJ, Hernandez‑Guillamon M, et al. Cerebral amyloid angiopathy and Alzheimer disease‑one peptide, two pathways. Nat Rev Neurol, 2020, 16(1):30-42.
    7. 7. Keage HA, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol, 2009, 9: 3.
    8. 8. Marc Dörner, Anthony Tyndall, Neuropsychiatric symptoms and lifelong mental activities in cerebral amyloid angiopathy - a cross-sectional study. Alzheimers Res Ther. 2024 Sep 4;16(1):196.
    9. 9. Andreas Charidimou, Gregoire Boulouis, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022 Aug;21(8):714-725.
    10. 10. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. Journal of Neuropathology and Experimental Neurology. 2003;62:1287-301.
    11. 11. Dietmar Rudolf Thal, W Sue T Griffin, et al. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 2008 Jun;115(6):599-609.
    12. 12. Aaron P Schultz, Reina W Kloet, et al. Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. Ann Neurol. 2019 Oct;86(4):616-625.
    13. 13. Arvanitakis Z, Leurgans SE, Wang Z, et al. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 2011; 69:320.
    14. 14. Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996; 46:1592.
    15. 15. Pfeifer LA, White LR, Ross GW, et al. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 2002; 58:1629.
    16. 16. Goos JD, Kester MI, Barkhof F, et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke 2009; 40:3455.
    17. 17. Greenberg SM, Briggs ME, Hyman BT, et al. Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996; 27:1333.
    18. 18. Obici L, Demarchi A, de Rosa G, et al. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol 2005; 58:639.
    19. 19. Kozberg MG, van Veluw SJ, Frosch MP, Greenberg SM. Hereditary cerebral amyloid angiopathy, Piedmont-type mutation. Neurol Genet 2020; 6:e411.
    20. 20. Maat-Schieman ML, Radder CM, van Duinen SG, et al. Hereditary cerebral hemorrhage with amyloidosis (Dutch): a model for congophilic plaque formation without neurofibrillary pathology. Acta Neuropathol 1994; 88:371.
    21. 21. van Etten ES, Gurol ME, van der Grond J, et al. Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy. Neurology 2016; 87:1482.
    22. 22. Nicoll JA, Burnett C, Love S, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997; 41:716.
    23. 23. Greenberg SM, Vonsattel JP, Segal AZ, et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998; 50:961.
    24. 24. Greenberg SM, Rebeck GW, Vonsattel JP, et al. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995; 38:254.
    25. 25. Biffi A, Sonni A, Anderson CD, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol 2010; 68:934.
    26. 26. Maxwell SS, Jackson CA, Paternoster L, et al. Genetic associations with brain microbleeds: Systematic review and meta-analyses. Neurology 2011; 77:158.
    27. 27. Rannikmäe K, Samarasekera N, Martînez-Gonzâlez NA, et al. Genetics of cerebral amyloid angiopathy: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2013; 84:901.
    28. 28. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:9649.
    29. 29. Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med 1995; 1:135.
    30. 30. McCarron MO, Nicoll JA, Ironside JW, et al. Cerebral amyloid angiopathy-related hemorrhage. Interaction of APOE epsilon2 with putative clinical risk factors. Stroke 1999; 30:1643.
    31. 31. McCarron MO, Nicoll JA, Stewart J, et al. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol 1999; 58:711.
    32. 32. O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000; 342:240.
    33. 33. Biffi A, Anderson CD, Jagiella JM, et al. APOE genotype and extent of bleeding and outcome in lobar intracerebral haemorrhage: a genetic association study. Lancet Neurol 2011; 10:702.
    34. 34. Vemuri P, Lesnick TG, Przybelski SA, et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain 2015; 138:761.
    35. 35. Chui HC, Zarow C, Mack WJ, et al. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol 2006; 60:677.
    36. 36. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277:813.
    37. 37. Bennett DA, Wilson RS, Arvanitakis Z, et al. Selected findings from the Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis 2013; 33 Suppl 1:S397.
    38. 38. Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013; 136:2697.
    39. 39. Troncoso JC, Zonderman AB, Resnick SM, et al. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 2008; 64:168.
    40. 40. Riekse RG, Leverenz JB, McCormick W, et al. Effect of vascular lesions on cognition in Alzheimer's disease: a community-based study. J Am Geriatr Soc 2004; 52:1442.
    41. 41. Kövari E, Gold G, Herrmann FR, et al. Cortical microinfarcts and demyelination affect cognition in cases at high risk for dementia. Neurology 2007; 68:927.
    42. 42. Schneider JA, Boyle PA, Arvanitakis Z, et al. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann Neurol 2007; 62:59.
    43. 43. Brickman AM, Honig LS, Scarmeas N, et al. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol 2008; 65:1202.
    44. 44. Xie S, Xiao JX, Gong GL, et al. Voxel-based detection of white matter abnormalities in mild Alzheimer disease. Neurology 2006; 66:1845.
    45. 45. Ighodaro ET, Abner EL, Fardo DW, et al. Risk factors and global cognitive status related to brain arteriolosclerosis in elderly individuals. J Cereb Blood Flow Metab 2017; 37:201.
    46. 46. Roher AE, Esh C, Rahman A, et al. Atherosclerosis of cerebral arteries in Alzheimer disease. Stroke 2004; 35:2623.
    47. 47. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005; 64:494.
    48. 48. Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 2012; 135:3749.
    49. 49. Dolan H, Crain B, Troncoso J, et al. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann Neurol 2010; 68:231.
    50. 50. de Leeuw FE, Korf E, Barkhof F, Scheltens P. White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. Stroke 2006; 37:2248.
    51. 51. Behl P, Bocti C, Swartz RH, et al. Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients. Arch Neurol 2007; 64:266.
    52. 52. Knopman DS, Griswold ME, Lirette ST, et al. Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study. Stroke 2015; 46:433.
    53. 53. Akoudad S, Wolters FJ, Viswanathan A, et al. Association of Cerebral Microbleeds With Cognitive Decline and Dementia. JAMA Neurol 2016; 73:934.
    54. 54. Schneider JA, Wilson RS, Bienias JL, et al. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004; 62:1148.
    55. 55. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002; 33:1152.
    56. 56. RosandJ, MuzikanskyA, et al. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol, 2005, 58(3): 459-462.
    57. 57. Charidimou A, Peeters A, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. Stroke 2012b; 43: 2324-30.
    58. 58. Calviere L, Cuvinciuc V, et al. Acute convexity subarachnoid hemorrhage related to cerebral amyloid angiopathy: clinicoradiological features and outcome. J Stroke Cerebrovasc Dis 2016; 25: 1009-16.
    59. 59. Charidimou A, Peeters AP, et al. Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. Neurology 2013c; 81: 1666-73.
    60. 60. Linn J, Halpin A, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010; 74: 1346-50.
    61. 61. Carcel C, Sato S, et al. Blood pressure management in intracranial hemorrhage: current challenges and opportunities. Curr Treatment Options Cardiovasc Med 2016; 18: 22.
    62. 62. Moulin S, Labreuche J, et al. Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study. Lancet Neurol 2016; 15: 820-9.
    63. 63. Kovari E, Herrmann FR, Hof PR, Bouras C. The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer’s disease. Neuropathol Appl Neurobiol 2013; 39: 498-509.
    64. 64. YehSJ, TangSC, et al. Pathogenetical subtypes of recurrent intracerebral hemorrhage: designations by SMASH-U classification system. Stroke, 2014, 45(9): 2636-2642.
    65. 65. Dominique Leitner, Tomas Kavanagh, et al. Differences in the cerebral amyloid angiopathy proteome in Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2024 Jul 22;148(1):9.
    66. 66. Filippi M, Cecchetti G, Spinelli EG, et al. Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies: a systematic review. JAMA Neurol, 2022,79(3):291-304.
    67. 67. Hampel H, Elhage A, Cho M,et al. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain, 2023,146(11):4414-4424.
    68. 68. ChenSJ, TsaiHH, et al. Advances in cerebral amyloid angiopathy imaging. Ther Adv Neurol Disord, 2019, 12: 1756286419844113.
    69. 69. FaridK, CharidimouA, et al. Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: a systematic critical update. Neuroimage Clin, 2017, 15: 247-263.
    70. 70. KlunkWE, EnglerH, NordbergA, et al. Imaging brain amyloid in Alzheimer′s disease with Pittsburgh compound-B. Ann Neurol, 2004, 55( 3): 306- 319.
    71. 71. RoweCC, AckermanU, BrowneW, et al. Imaging of amyloid beta in Alzheimer′s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol, 2008, 7( 2): 129- 135.
    72. 72. WongDF, RosenbergPB, ZhouY, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med, 2010, 51( 6): 913- 920.
    73. 73. SerdonsK, TerwingheC, VermaelenP, et al. Synthesis and evaluation of 18F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer′s disease. J Med Chem, 2009, 52( 5): 1428- 1437.
    74. 74. CharidimouA, FaridK, et al. Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry, 2018, 89(4): 410-417.
    75. 75. CharidimouA, FaridK, et al. Amyloid-PET in sporadic cerebral amyloid angiopathy: a diagnostic accuracy meta-analysis. Neurology, 2017, 89(14): 1490-1498.
    76. 76. JohnsonKA, GregasM, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol, 2007, 62(3): 229-234.
    77. 77. LyJV, DonnanGA, et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology, 2010, 74(6): 487-493.
    78. 78. LiX, WangX, SuL, et al. Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline. BMJ Open, 2019, 9(7): e028188.
    79. 79. Cecilia Boccalini, Federica Ribaldi, et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Alzheimers Dement. 2024 Jan;20(1):221-233.
    80. 80. Emma M Coomans, Danielle van Westen, et al. Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation. Brain. 2024 Mar 1;147(3):949-960.
    81. 81. van EttenES, VerbeekMM, van der GrondJ, et al. β-Amyloid in CSF: biomarker for preclinical cerebral amyloid angiopathy. Neurology, 2017, 88(2): 169-176.
    82. 82. CharidimouA, FriedrichJO, GreenbergSM, et al. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: a meta-analysis. Neurology, 2018, 90(9): e754-e762.
    83. 83. Andreas Zellner, Stephan A Müller, et al. Proteomic profiling in cerebral amyloid angiopathy reveals an overlap with CADASIL highlighting accumulation of HTRA1 and its substrates. Acta Neuropathol Commun. 2022 Jan 24;10(1):6.
    84. 84. Theophania Ashleigh, Russell H Swerdlow, M Flint Beal. The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis. Alzheimers Dement. 2023 Jan;19(1):333-342.
    85. 85. Christina Ising, Carmen Venegas 1, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019 Nov;575(7784):669-673.
    86. 86. Benjamin Falcon, Jasenko Zivanov, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019 Apr;568(7752):420-423.
    87. 87. Yuting Nie, Changbiao Chu, et al. Lipid metabolism and oxidative stress in patients with Alzheimer's disease and amnestic mild cognitive impairment. Brain Pathol. 2024 Jan;34(1):e13202.
    88. 88. Stephen Salloway, Spyros Chalkias, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. 2022 Jan 1;79(1):13-21.
    89. 89. John R Sims, Jennifer A Zimmer, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023 Aug 8;330(6):512-527.
    90. 90. Reisa A Sperling, Michael C Donohue, et al. Trial of Solanezumab in Preclinical Alzheimer's Disease. N Engl J Med. 2023 Sep 21;389(12):1096-1107.
    91. 91. Greenberg SM, Rebeck GW, et al. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38(2):254-9.
    92. 92. Racke MM, Boone LI, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005;25(3):629-36.
    93. 93. Piazza F, Greenberg SM, et al. Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related infammation: implications for amyloid-modifying therapies. Ann Neurol. 2013;73(4):449-58.
    94. 94. Boche D, Zotova E, et al. Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain. 2008;131(Pt 12):3299-310.
    95. 95. Nicholas J Reish, Pouya Jamshidi, Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke. N Engl J Med. 2023 Feb 2;388(5):478-479.

    How to Cite

    “Biomarkers of Cerebral Amyloid Angiopathy and Neuropathological Relationship With Alzheimer’s Disease”. Human Brain, vol. 3, no. 4, Mar. 2025, https://doi.org/10.37819/hb.4.2053.
    ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
    Download Citation
    Endnote/Zotero/Mendeley (RIS) BibTeX

    How to Cite

    “Biomarkers of Cerebral Amyloid Angiopathy and Neuropathological Relationship With Alzheimer’s Disease”. Human Brain, vol. 3, no. 4, Mar. 2025, https://doi.org/10.37819/hb.4.2053.

    HTML
    0

    Total
    0

    Citations
    undefined

    Share

    Search Panel

    Ting Jiang
    Google Scholar
    Pubmed
    JDMFS Journal

    Wenying Qiu
    Google Scholar
    Pubmed
    JDMFS Journal

    Jun Ni
    Google Scholar
    Pubmed
    JDMFS Journal

    Yuhui Sha
    Google Scholar
    Pubmed
    JDMFS Journal

    Xiangsha Yin
    Google Scholar
    Pubmed
    JDMFS Journal

    Xiaojing Qian
    Google Scholar
    Pubmed
    JDMFS Journal

    Downloads

    Article Details

    Most Read This Month

    Most read articles by the same author(s)

    License

    Copyright (c) 2025 Ting Jiang, Wenying Qiu, Jun Ni, Yuhui Sha, Xiangsha Yin, Xiaojing Qian

    Creative Commons License

    This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

    Most read articles by the same author(s)

    Copyright © 2023 EurAsia Academic Publishing Group. All rights reserved